Drug
Peposertib clinical trials
Also written MSC2490484A, M3814 and Nedisertib.
- studies test it
- 16
- open now
- 3
- in phase 3
- 0
- first study started
- 2014
Keep track of what changes. Save the peposertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 4 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 16
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 10
National Cancer Institute (NCI) (9) · EMD Serono Research & Development Institute, Inc. (4) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Merck KGaA, Darmstadt, Germany (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
Often tested with
Tested in the same studies.
Avelumab (3) · Liposomal doxorubicin (2) · Doxorubicin (2) · Cytarabine (2) · Etoposide (2) · Cisplatin (2) · Lutetium Lu 177 dotatate (1) · Etoposide phosphate (1)
Studies
Open first, then newest update. How each study uses peposertib is read from its arms, and is right about nine times in ten.
Testing it · 16
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaRecruitingPhase 1National Cancer Institute (NCI)NCT05711615Written as Peposertib
- Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT05687136Written as Peposertib
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Peposertib
- Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic CancerSuspendedPhase 1/2National Cancer Institute (NCI)NCT04172532Written as Peposertib
- Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take CisplatinActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04533750Written as Peposertib
- Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04071236Written as Peposertib
- Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04068194Written as Peposertib
- A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04092270Written as Peposertib
- Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04750954Written as Peposertib
- Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03983824Written as Peposertib
- Study of Avelumab-M3814 CombinationsCompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT03724890Written as M3814
- Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With RadiotherapyCompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT02516813Written as M3814 100 mg
- Study of Peposertib in Combination With Capecitabine and RT in Rectal CancerCompletedPhase 1/2EMD Serono Research & Development Institute, Inc.NCT03770689Written as Peposertib 50 mg
- Effect of Food on Peposertib PKCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04702698Written as Peposertib
- Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)TerminatedPhase 1EMD Serono Research & Development Institute, Inc.NCT03116971Written as M3814
- Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic LeukemiaCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT02316197Written as MSC2490484A (M3814)
Given in every arm · 1 — peposertib is usual care beside what is tested
Codes
What other systems call peposertib · ClinicalTrials.gg INT001600
- MeSH (NLM) C000716216peposertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) GN429E725APEPOSERTIBConfirmed FDA, NLM
- NCI Thesaurus C120036PeposertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716216 | peposertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | GN429E725A | PEPOSERTIB | Confirmed FDA, NLM |
| NCI Thesaurus | C120036 | Peposertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.